HighTower Advisors’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
HighTower Advisors's BEAM Position: Q3 2026 in Review
HighTower Advisors increased its Beam Therapeutics (BEAM) stake by 35% in Q3 2026, buying an estimated $90.8K and bringing the position to 12,551 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #3199.
HighTower Advisors first reported a position in BEAM in Q4 2021 and has held it in 7 quarters since. The position peaked at $319K in Q2 2026. 260 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- HighTower Advisors held 12,551 shares of Beam Therapeutics worth $307K as of Q3 2026.
- HighTower Advisors bought 3,262 Beam Therapeutics shares in Q3 2026, an estimated $90.8K.
- Beam Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3199 holding.
- HighTower Advisors first reported a position in Beam Therapeutics in Q4 2021 and has held it in 7 quarters since.
- HighTower Advisors's Beam Therapeutics position peaked at $319K in Q2 2026.
- 260 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.